Abstracts tagged "Vaccination"

Abstract Number: 1607 • ACR Convergence 2021
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
Rebecca Sadun¹, Mithu Maheswaranathan¹, Megan Clowse², Kai Sun¹, Jennifer Rogers¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Michael Paley¹, Parakkal Deepak², Wooseob Kim², Monica Yang³, Alex Carividi³, Emanuel Demissie³, Alia A. El-Qunni,², Alem Haile², Katherine Huang², Baylee Kinnett², Mariel Liebeskind², Zhouming Liu², Lily E. McMorrow², Diana Paez³, Niti Pawar³, Dana Perantie², Rebecca E. Schriefer², Shannon Sides², Mahima Thapa², Sewuese Akuse⁴, Samantha Burdess², Abbey Rose², Lynne Mitchell², Salim Chahin², Matthew Ciorba², Jonathan Graf⁵, Patricia Katz³, Mehrdad Matloubian³, Jane O'Halloran², Rachel Presti², Gregory Wu², Sean Whelan², William Buchser², Lianne Gensler⁶, Mary Nakamura⁷, Ali H Ellebedy² and Alfred Kim², ¹Washington University in St. Louis, Olivette, MO, ²Washington University School of Medicine, St. Louis, MO, ³University of California San Francisco, San Francisco, CA, ⁴Washington University School of Medicine, St Louis, MO, ⁵Ucsf, San Francisco, CA, ⁶Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁷UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 0640 • ACR Convergence 2021
Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
Manjeet Bhamra¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Daniel Magliulo¹, Stefanie Wade² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
Abstract Number: 803 • 2019 ACR/ARP Annual Meeting
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Kenan Barut ¹, Amra Adrovic ², Sezgin Sahin ³, Mehmet Yıldız ², Oya Koker ², Gamze Yalcin ², Omer Faruk Beser ⁴, Bekir Kocazeybek ⁵, Pelin Yuksel ⁵ and Ozgur Kasapcopur⁶, ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ²Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, ⁵Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ⁶Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is…
Abstract Number: 1804 • 2019 ACR/ARP Annual Meeting
Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients
Emma Stevens¹, Michael Weinblatt ¹, Elena Massarotti ², Frances Griffin ¹, Srinivas Emani ¹ and Sonali Desai ³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical S, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) and other systemic diseases (SD) are at an increased risk of developing Herpes Zoster (HZ) due to either the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].